Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Semaglutide
40
CHF
CHF 40.00
In stock
AG-CP3-0040-M0011 mgCHF 40.00
AG-CP3-0040-M0055 mgCHF 110.00
AG-CP3-0040-M02525 mgCHF 440.00
AG-CP3-0040-M100100 mgCHF 1'200.00
BULK available!
Research Use Only (RUO). NOT ALLOWED FOR USE IN HUMANS.
| Product Details | |
|---|---|
| Synonyms | Semaglutide (free acid); NN 9535; NNC 0113-0217; Ozempic |
| Product Type | Chemical |
| Properties | |
| Formula |
C187H291N45O59 |
| MW | 4113.6 |
| Sequence |
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| CAS | 910463-68-2 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White lyophilized powder. |
| Solubility | Soluble in aqueous solution (5% AcOH) (1mg/ml). |
| Identity | Determined by MS and EA. |
| InChi Key | DLSWIYLPEUIQAV-CIIFZSTISA-N |
| Smiles | CC(C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@H](O)C)([H])C(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(N[C@H](C(N[C@@H]CC(C)C)C(N[C@@H]C(C)C)C(N[C@@H]CCCNC(N)=N)C(NCC(N[C@@H]CCCNC(N)=N)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)CC1=CNC2=C1C=CC=C2)=O)C)=O)=O)CC3=CC=CC=C3)=O)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H]C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)C)=O)C)=O)=O)=O)=O)=O)CC(C=C4)=CC=C4O)=O)=O)=O)=O)CC(O)=O)=O)=O)=O)CC5=CC=CC=C5)=O)=O)=O)=O)(C)NC([C@@H](N[H])CC6=CN=CN6)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Glucagon-like peptide-1 (GLP-1) receptor agonist.
- Antidiabetic agent against type 2 diabetes (T2D). Stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner.
- Longer-acting alternative to liraglutide. Chemically similar to glucagon-like peptide-1 (GLP-1), with two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and derivatized at lysine 26.
- Antiobesity activity. Reduces energy intake, likely mechanisms for semaglutide-induced weight loss include less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods.
Product References
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide: J. Lau, et al.; J. Med. Chem. 58, 7370 (2015)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes: S.P. Marso, et al.; N. Engl. J. Med. 375, 1834 (2016)
- Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity: J. Blundell, et al.; Diabetes Obes. Metab. 19, 1242 (2017)
- Semaglutide-the 'new kid on the block' in the field of glucagon-like peptide-1 receptor agonists? C. Guja & R. Danciulescu Miulescu; Ann. Transl. Med. 5, 475 (2017) (Review)
- Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice: S. Iwai, et al.; Biochim. Biophys. Acta Mol. Basis Dis. ahead of print (2023)
Related Products
